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Biopsy needle advancement during 
Bone Marrow aspiration increases 
Mesenchymal stem cell 
concentration
Anne E. Peters and Ashlee E. Watts*
Department of Large Animal Clinical Sciences, Texas A&M University, College Station, TX, USA
Point-of-care kits to concentrate bone marrow (BM)-derived mesenchymal stem cells 
(MSCs) are used clinically in horses. A maximal number of MSCs per milliliter of marrow 
aspirated might be desired prior to use of a point-of-care system to concentrate MSCs. 
Our objective was to test a method to increase the number of MSCs per milliliter of 
marrow collected. We collected two BM aspirates using two different collection tech-
niques from 12 horses. The first collection technique was to aspirate BM from a single 
site without advancement of the biopsy needle. The second collection technique was 
to aspirate marrow from multiple sites within the same sternal puncture by advancing 
the needle 5 mm three times for BM aspiration from four sites. Numbers of MSCs in 
collected BM were assessed by total nucleated cell count of BM after aspiration, total 
colony-forming unit-fibroblast (CFU-F) assay, and total MSC number at each culture pas-
sage. The BM aspiration technique of four needle advancements during BM aspiration 
resulted in higher initial nucleated cell counts, more CFU-Fs, and more MSCs at the first 
passage. There were no differences in the number of MSCs at later passages. Multiple 
advancements of the BM needle during BM aspiration resulted in increased MSC con-
centration at the time of BM collection. If a point-of-care kit is used to concentrate 
MSCs, multiple advancements may result in higher MSC numbers in the BM concentrate 
after preparation by the point-of-care kit. For culture expanded MSCs beyond the first 
cell passage, the difference is of questionable clinical relevance.
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inTrODUcTiOn
Grafting of autologous bone marrow (BM)-derived cells, as raw BM (1), concentrated BM (2), or 
BM-derived culture expanded mesenchymal stem cells (MSCs) (3) is used in the horse as a regen-
erative therapy. Numerous differences exist between each of these autologous therapies. One major 
difference is the timing of therapeutic application. Both raw BM and concentrated BM can be used 
for point-of-care therapy, whereas BM-derived MSCs typically undergo a 2- to 4-week culture period 
(4) prior to implantation.
Concentrated BM, or bone marrow aspirate concentrate (BMAC), is BM that has been processed 
to increase the concentration of the mononuclear portion, which should also reflect an increase in 
the concentration of MSCs. The enhanced efficacy of BMAC compared to BM was first described in 
1989, with improved healing of delayed union in rabbits (5). Since then, the ability to increase the 
FigUre 1 | Photograph of bone marrow (BM) aspiration needle 
showing (a) stylet, (B) needle, (c) aspiration holes, and (D) centimeter 
marks used to measure 2 cm distance from the ventral cortical 
surface of the sternum.
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mononuclear fraction in BMAC compared to BM has been well 
described in multiple species ranging from an increase of 2.4- to 
5-fold in people (6), 7-fold in dogs (7), 3.5-fold in pigs (8), and 
5- to 19-fold in the horse (9). The increase in MSC concentration 
within the mononuclear fraction of BMAC versus unprocessed 
BM is well accepted and relevant to therapeutic applications. 
In people with atrophic tibial diaphyseal non-union, treatment 
success with either BM or BMAC was related to the number of 
progenitors in the graft (10).
Most BMAC systems for the horse require a minimum of 
60 ml of BM (2) and anti-coagulant for the system to separate 
nucleated cells, and presumably the stem cells, from other BM 
components. However, it is well known that the contamination 
of peripheral blood in large volume BM aspirates results in a 
lower concentration of MSCs per milliliter of BM aspirated. Thus, 
recommended BM aspirate volumes for patient-side regenerative 
medicine applications in people are 2–10 ml of BM per aspira-
tion site (11, 12). In the horse, the same effect of MSC dilution 
in large volume BM aspirates was identified when the numbers 
of colony-forming unit-fibroblasts (CFU-Fs) in successive 5-ml 
aliquots of BM were compared (13). Because of the MSC dilu-
tion in large volume aspirates, Ishihara et al. tested a specialized 
needle that allows for collection of BM from several locations 
within one sternal puncture in anesthetized horses. Use of the 
multidirectional needle for BM collection allowed them to collect 
BM aspirates from three different sites within the marrow space 
without removing, replacing, or advancing the needle beyond 
their initial placement. Instead of moving the needle to a new 
space within the sternal marrow space, they twisted a second 
cannula within the needle, which redirected BM flow from and 
to each of the three sites. Use of their multidirectional needle 
resulted in an increased frequency of BMAC samples character-
ized as “high” in progenitor cells but no differences in the MSC 
concentration in BM aspirate samples (9).
Maximizing the number of MSCs in the BM aspirate prior to 
concentration with a device would be important to enhance MSC 
concentration of the final BMAC product. We wanted to develop 
a technique in standing and sedated horses that would collect 
sufficient BM volume for most BMAC systems with a higher 
concentration of MSCs and a reasonable number of bone punc-
ture sites. The objective of our study was to determine if multiple 
advancements of the BM biopsy needle from the same sternal 
puncture would result in a higher number of MSCs in 56-ml of 
BM compared to collection from a single site (SS). We hypoth-
esized that multiple advancements of the BM needle would result 
in BM aspirates with higher total nucleated cell count (TNCC). 
To test this, we collected BM using two different techniques from 
12 horses and compared TNCC of BM aspirates, the CFU-F assay 
of cultured BM, and the number of culture expanded MSCs at 
the first, second, and third passages from BM collected from a SS 
versus multiple sites (MS).
MaTerials anD MeThODs
Bone Marrow collection
All animal procedures were approved by the institution’s animal 
care and use committee (IACUC 2013-0097). BM aspirations 
were performed in 12 healthy university-owned horses, and no 
horses were euthanized for this study.
Bone marrow aspiration was performed from the sternal mar-
row spaces 4 and 5 using an 11-gage × 10.16 cm BM biopsy needle1 
with mild sedation of horses (xylazine2; 0.4 mg/kg body weight 
IV) and application of local anesthetic in the subcutaneous tissues 
(Figure 1). Selection of the site for the fourth and fifth space was 
made adjacent to the point of the elbow in a square stance and 
3–4 cm caudal to that. Collection from the fourth or fifth stern-
ebrae was randomized for the SS and MS aspirations. For the SS 
collection, the biopsy needle was advanced 2 cm from the ventral 
cortical surface of the sternum (13), the stylet was removed, and 
56 ml of BM was aspirated into a 60-ml syringe pre-filled with 
5,000 U of heparin sodium injection.3 For the MS collection, a 
technique similar to that reported by Hernigou et al. was used 
(10). The BM needle was advanced as for the SS, but only 7 ml of 
marrow was collected. After the first 7 ml of BM, the needle was 
rotated 45°, and an additional 7 ml of BM was collected. After the 
first 14 ml of BM was collected, the stylet was replaced, and the 
biopsy needle was advanced 5 mm dorsally followed by collection 
of 7 ml of BM, rotation of the needle, and collection of 7 ml of 
BM. This advancement and BM collection followed by rotation 
were repeated two additional times, for a total BM collection of 
56 ml and a total distance from the ventral cortical surface of the 
sternum of 3.5 cm, or 1.5 cm from the initial aspiration site.
1 Ranfac Corporation, Avon, MA, USA
2 VetOne®, Boise, ID, USA
3 Sagent Pharmaceuticals, Schaumburg, IL, USA
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colony-Forming Unit-Fibroblast assay
The number of CFU-Fs per milliliter of BM from SS and MS was 
determined by seeding 1  ml of undiluted and unmanipulated 
BM to a 10  cm tissue culture dish4 (246  cm2) containing 9  ml 
culture medium [Dulbecco’s modified Eagle’s medium (DMEM),5 
1 g/l glucose supplemented with 10,000 U/ml Penicillin, 10 mg 
streptomycin sulfate, 25  μg/ml amphotericin B6; 2.5% HEPES 
buffer7; 10 μg/ml human recombinant basic fibroblastic growth 
factor (see text footnote 7); and 10% fetal bovine serum (FBS)]8 
and maintained at 37°C in 5% CO2, humidified air. Media was 
exchanged three times per week. Plates were inspected and pho-
tographed daily with an Olympus CKX419 microscope. When 
colonies approached coalescence, media was removed, and the 
colonies were stained with 3% crystal violet10 similar to Franken 
et  al. (14). After plates dried for 24  h, colonies were manually 
counted without magnification by an observer masked to treat-
ment group.
Total nucleated cell count
Red blood cell lysis on 10 ml of BM was performed to obtain an 
initial TNCC. BM was mixed with a sterile red blood cell lysis 
solution (7.7  mg/ml NH4CL11; 2.06  mg/ml hydroxymethane– 
aminomethane12; pH 7.2) for 2  min, and then centrifuged at 
300 × g for 10 min at 4°C. After aspirating supernatant, the cell 
pellet was resuspended and mixed with lysis solution and centri-
fuged at 300 × g for 10 min at 4°C. The cell pellet was washed with 
DPBS13 and then centrifuged for 5 min at 300 × g at 4°C. Cells 
were resuspended in isolation medium at a volume equal to the 
original volume of BM aspirate or 10 ml. Samples were diluted 
1–10 and a 100-μl sample was used for manual counting of nucle-
ated cells with fluorescein diacetate14 and propidium iodide (see 
text footnote 14).
isolation and expansion of Mscs
Bone marrow aspirate was mixed at a 1:1 ratio with culture 
medium (described above) and seeded directly onto tissue cul-
ture flasks15 at 28 ml BM per 175 cm2 and maintained at 37°C 
in 5% CO2 humidified air. After 24 h, the same volume of media 
was added again to the BM media mixture, and half the resultant 
volume was transferred to a new flask, doubling the number of 
flasks. Medium was exchanged three times per week. Cells were 
detached from tissue culture flasks when colonies or monolayers 
approached 70–80% of confluence with 5 ml Trypsin EDTA16 per 
4 Bio Basic, Amherst, NY, USA
5 DMEM 1 g/l glucose Mediatech, Manassas, VA, USA
6 Mediatech, Inc., Manassas, VA, USA
7 Corning, Corning, NY, USA
8 HyClone, Thermo Scientific, Logan, UT, USA
9 Olympus, Center Valley, PA, USA
10 Crystal Violet Sigma-Aldrich, St. Louis, MO, USA
11 Avantor Performance Materials, Macron Fine Chemicals, Center Valley, PA, USA
12 Sigma, St. Louis, MO, USA
13 Lonza, Walkersville, MD, USA
14 EMD Chemicals, Inc., Calbiotech, San Diego, CA, USA
15 175 cm2 Polystyrene Tissue Culture Flask with Vented Caps Corning, Corning, 
NY, USA
16 Trypsin EDTA, Corning, Corning, NY, USA
175 cm2, washed, counted, and reseeded at 5,000 MSCs/cm2 until 
passage 3, when the final expanded MSC number was determined.
Validation of Mscs
At the conclusion of isolation and expansion, the MSCs from MS 
and SS were combined and the cell surface marker expression for 
MHCII,17 CD44 (see text footnote 17), CD29,18 CD45,19 and CD90 
(see text footnote 19) were determined for MSCs from each horse 
using flow cytometry with antibodies that have been previously 
validated in the horse (15, 16). Cryopreserved cells were thawed, 
and the concentration was adjusted to make aliquots of one mil-
lion cells suspended in DPBS. Blocking was performed by 20 min 
incubation with 10 μl undiluted goat serum. MSCs were pelleted 
by centrifugation at 400 × g for 5 min followed by incubation with 
antibody dilutions. For MHCII and CD29 and CD44, a 1:100 dilu-
tion with conjugated primary antibody was used. For CD90 and 
CD45, a 1:400 dilution was used with primary and conjugated 
secondary antibody. Unstained MSCs were used as controls.
Multipotency was tested for SS and MS combined MSCs from 
all 12 horses and reported as positive or negative. Tri-lineage dif-
ferentiation was induced by techniques that have been described 
previously (17–19). For chondrogenic differentiation, aliquots of 
MSCs (500,000) were centrifuged at 300 × g for 5 min to pellet the 
cells. To induce chondrogenic differentiation, supernatant was 
aspirated, and 1 ml of chondrogenic induction media [DMEM20 
4.5  g/l glucose, supplemented with 10,000  U/ml Penicillin, 
10  mg streptomycin sulfate, 25  μg/ml amphotericin B; 2.5% 
HEPES buffer; 0.2% transforming growth factor β,21 301.89 μg 
dexamethasone,22 50 μg/ml l-ascorbic acid (see text footnote 22), 
40 μg/ml proline (see text footnote 22), 1% ITS+ premix (see text 
footnote 7), and 1% FBS] was added on top of the pellet. Media 
was exchanged three times per week for 21 days. Pellets were fixed 
in 4% formaldehyde (see text footnote 22) for 10 min followed 
by routine processing, embedding, sectioning, and staining with 
toluidine blue (see text footnote 22).
Adipogenic differentiation of MSCs was induced by seeding a 
10-cm tissue culture dish with 1,000 MSCs/cm2. At 70% conflu-
ence, existing media was removed and replaced with adipogenic 
induction media [DMEM Ham’s/F12 1:1,23 supplemented with 
10,000  U/ml penicillin, 10  mg streptomycin sulfate, 25  μg/
ml amphotericin B, 5% rabbit serum (see text footnote 21), 
33 μM/l biotin (see text footnote 22), 17 μM pantothenate (see 
text footnote 22), 1 μM/l insulin (see text footnote 22), 1 μM/l 
dexamethasone, 225 μl isobutylmethylxanthine (see text footnote 
22), 89 μl rosiglitazone (see text footnote 22), and 3% FBS] for 
3 days. Media was replaced with adipogenic maintenance media 
(adipogenic induction media without isobutylmethylxanthine 
and rosiglitazone) for an additional 3 days followed by staining 
with oil red O (see text footnote 22).
17 Bio-Rad, Raleigh, NC, USA
18 Beckman Coulter, Brea, CA, USA
19 VMRD Inc., Pullman, WA, USA
20 DMEM 4.5 g/l glucose Mediatech, Manassas, VA, USA
21 Life Technologies, Grand Island, NY, USA
22 Sigma-Aldrich, St. Louis, MO, USA
23 DMEM F12 Hams 1:1 mix, Mediatech, Manassas, VA, USA
FigUre 3 | Total nucleated cell count (mean, standard deviation) per 
milliliter of raw bone marrow aspirated using a single site (ss) or a 
multiple site (Ms) technique during bone marrow aspiration. There 
were significantly more nucleated cells in BM collected with the MS technique 
(p = 0.01, paired t-test).
FigUre 2 | colony-forming-unit-fibroblast (cFU-F) assay from bone 
marrow aspirates using a single site (ss) or a multiple site (Ms) 
technique during bone marrow aspiration (mean, standard deviation). 
There were significantly more CFU-Fs from bone marrow collected with the 
MS technique (p = 0.02, paired t-test).
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For osteogenic differentiation, MSCs were seeded on 10 cm 
culture dishes at 1,000 MSCs/cm2. At 70% confluence, media was 
exchanged for osteogenic induction media [DMEM Ham’s/F12 
1:1, supplemented with 10,000 U/ml penicillin, 10 mg strepto-
mycin sulfate, 25 μg/ml amphotericin B, 20 nM/l dexamethasone, 
50 μg/ml ascorbic acid, 10 μM/l glycerophosphate (see text foot-
note 22), and 10% FBS], and cultures were maintained for 14 and 
21 days. Media was exchanged three times per week. Cells were 
stained with 2% alizarin red (see text footnote 22).
statistical analysis
Data were imported to a commercially available statistical analy-
sis program (Statistix 9)24 and tested for normality. Paired data for 
each horse were compared using Wilcoxon-signed-rank test or 
paired t-test as appropriate for data normality. Differences were 
considered significant when p ≤ 0.05 (one-tailed).
resUlTs
BM collection
Twelve female horses ranging in age from 7 to 16 years were used 
for BM collection. They were all of Quarter Horse type. BM col-
lection went well without incident. Horses were under our care 
for the following 6 months. No adverse events were recorded.
cFU-F assay
The number of CFU-F from the MS technique was significantly 
(mean; SD) higher than from the SS technique [SS, 33 (27.6); MS, 
51 (36.4); p = 0.02; Figure 2].
Total nucleated cell count
The TNCC from the MS technique was significantly (mean; SD) 
higher than from the SS technique [SS 14.4 × 106 (7.6 × 106); MS 
20.9 × 106 (7.0 × 106); p = 0.01; Figure 3].
isolation and expansion of Mscs
The number of MSCs at the first passage was significantly 
(median; interquartile range) higher at the first passage with MS 
compared to SS aspiration [SS 1.5 × 106 (0.52 × 106–5.16 × 106); 
MS 3.15 × 106 (1.65 × 106–10.98 × 106); p = 0.02; Figure 4], at 
the second passage [SS 4.95 × 106 (2.17 × 106–11.77 × 106); MS 
7.0 ×  106 (3.16 ×  106–13.57 ×  106); p =  0.1; Figure  4], and at 
the third passage [SS 7.84 ×  106 (5.95 ×  106–18.7 ×  106); MS 
15.45 × 106 (9.15 × 106–21.97 × 106); p = 0.2; Figure 4], there was 
no significant difference in the number of cells between the two 
aspiration techniques.
Validation of cell Mscs
The cell surface marker profile was consistent with previous 
reports in the horse (15). MSCs from 8 of 12 horses were negative 
for MHCII expression, 11 of the 12 were positive for CD90 and 
CD29 and 12 of 12 were negative for CD45. MSCs from one horse 
displayed mixed expression of both CD90 and CD29.
24 Statistix Analytical Software, Tallahassee, FL, USA
All MSCs were positive for tri-lineage differentiation 
(Figure 5).
DiscUssiOn
Our objective was to determine whether multiple advance-
ments (MS) within the same sternal puncture would result in 
a greater number of MSCs in a 56-ml BM aspirate compared 
to collection of 56 ml BM from a single site (SS). We found a 
significantly higher number of nucleated cells in the BM aspi-
rate, and after culture a significantly higher number of CFU-Fs 
and a significantly higher number of MSCs at the first passage 
from MS compared to SS aspirates. The increase in CFU-F 
number and MSC number at the first passage supports that the 
increased TNCC was due at least in part to a higher number of 
FigUre 5 | examples of Mscs after (a) adipogenic, (B) osteogenic, and (c) chondrogenic induction and staining with resulting in lipid, calcium, and 
proteoglycan accumulation. Original magnification 200× (a,c) and 40× (B); scale bar = 100 μm (a,c) or 500 μm (B).
FigUre 4 | Total number of mesenchymal stem cells (Mscs; mean, standard deviation) at the each passage from bone marrow aspirates using a single 
site (ss) or a multiple site (Ms) technique during bone marrow (BM) aspiration. There were significantly more MSCs from BM collected with the MS technique 
(p = 0.02, Wilcoxon-signed rank test). The number of MSCs at passages 2 and 3 were not significantly different between SS and MS techniques (p = 0.1; p = 0.2).
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MSCs in the BM aspirate. At later passages, the total number 
of MSCs was not different between SS and MS. We think this 
is because of the rapid growth (4) of MSCs that once isolated, 
quickly overcome differences in initial MSC concentration. This 
information is important to the equine veterinarian using BM 
in patient-side BMAC applications, where large BM volumes 
are required (most BMAC kits use a total BM volume of 60 ml) 
and a higher concentration of MSCs in the BM aspirate prior to 
concentration in the kit could result in higher MSC numbers in 
the final BMAC product.
Estimates of MSC concentration in BM are 0.001–0.01% (20). 
This is probably an underestimate of the MSC concentration 
because it was determined using aspirate volumes of 10–30 ml 
of BM aspirate per site (20). Regardless, the total number of 
MSCs in the aspirate, combined with the efficiency of the BMAC 
system, ultimately determines the number of MSCs in the BMAC 
product. Therefore, increasing the concentration of MSCs in the 
BM aspirate is a step the clinician can take to maximize MSC 
number in the final BMAC preparation.
To maximize progenitor concentration using recommenda-
tions from human medicine of 2  ml BM per aspiration site as 
suggested by Muschler et al. (12) and 10 ml BM per aspiration 
site as suggested by Hernigou et al. (21) 30 and 6 separate aspira-
tions, respectively, would be required to collect 60 ml, which is 
the typical BM volume for currently available veterinary BMAC 
kits (3, 7, 9). To minimize peripheral blood contamination with 
a more reasonable number of bone punctures, Thoesen et  al. 
collected 7  ml of BM from five separate aspiration sites from 
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each humerus in dogs (7). To achieve the same goal with even 
fewer cortical bone penetrations in the horse, another group 
described a specialized needle that increased the frequency of 
BMAC samples characterized as “high” in progenitor cells but 
resulted in no differences in MSC concentration of BM aspirates 
(9). We think our MS technique is similar to the multidirectional 
needle, in that BM is collected from different sites within a single 
sternal puncture; however, in contrast to Ishihara et al., we found 
significant differences in MSC concentration in the original BM 
aspirate. Our MS technique with multiple manual advancements 
of the biopsy needle might be more efficient at entering naive 
lacunae than the multidirectional needle. Increased efficiency 
could have resulted in less peripheral blood contamination and 
a higher MSC concentration in the BM aspirate even without a 
BMAC processing step.
We think the 3 advancements of 5 mm each of the biopsy 
needle are responsible for the increased MSC concentration 
due to reduced peripheral blood contamination. Histological 
specimens after BM collection have demonstrated a minimal 
number of lacunae are penetrated during BM aspiration and 
each lacuna is filled with hemorrhage (13). Without biopsy nee-
dle advancement, we think continued aspiration from the same 
site simply collects hemorrhage from the penetrated lacunae, 
rather than additional progenitors as has been demonstrated 
previously (13). By advancing the biopsy needle between 
aspirations, new bony trabeculae are penetrated, allowing 
BM collection of MSC-rich BM rather than BM hemorrhage. 
Additionally, the 45° twist of the needle at each site of aspira-
tion repositions the holes along the side of the needle and could 
also communicate with new lacunae.
One concern about the MS technique might be the increased 
risk of cardiac puncture with multiple advancements of the 
biopsy needle. The dorsoventral dimension of the marrow space, 
not including the cortical bone thickness, within the fourth and 
fifth sternebrae of the horse is approximately 6.0 and 4.5  cm, 
respectively (13). Routine technique for the aspiration of BM 
from the equine sternum is to advance the biopsy needle to a 
depth of 2-cm from the ventral cortex (13). This depth would 
leave a minimum additional 4 and 2  cm, respectively, of mar-
row space that the needle could be advanced into prior to 
contacting the dorsal cortex. Our MS technique results in an 
additional advancement of 1.5  cm after the initial placement, 
2  cm from the ventral surface of the sternum. Therefore, with 
accurate placement of the biopsy needle on midline, and careful 
needle advancement in 5 mm increments, we think the risk of 
penetration of the dorsal cortex is very low. Certainly, we did 
not have any complications in this group of 12 horses where we 
utilized this technique and we have not had complications on the 
approximately 120 clinical horses where we used the technique 
for BM aspiration.
A limitation of our study is that we only have indirect proof 
of increased MSC number with the MS technique. However, the 
increased TNCC in MS samples is unlikely to be caused by an 
increase in the white blood cell population, but rather an increase 
in progenitor populations, including MSCs. This is supported by 
the increase in numbers of colonies in the CFU-F assay from 
MS samples that reflect a higher concentration of MSCs in the 
original aspirate and the higher number of MSCs from MS at the 
first passage (22).
In conclusion, we tested two techniques for collection of 
56 ml of BM from the equine sternum. In our 12 horses, use of 
the MS technique resulted in a higher concentration of MSCs 
in the BM aspirate as compared to the SS technique. The higher 
concentration of MSCs was determined by comparing the TNCC 
and the CFU-F ability of BM aspirates as well as the total number 
of MSCs at the first passage during culture expansion. Based on 
our findings, the MS technique for BM aspiration might be use-
ful in same day applications such as BMAC or BM grafting if 
an increased number of MSCs in the BMAC product is desired. 
Future studies could test whether increased MSC concentration 
using the MS technique causes a greater treatment effect of 
BMAC compared to using BM from the SS technique. The MS 
technique may also be useful if the clinician wanted to use very 
early passage MSCs.
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